drugset / Trial / NCT01717040

Pioglitazone for the Treatment of Bipolar Depression

NCT01717040

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective is to test the hypothesis that adjunctive pioglitazone is more effective than placebo for the relief of acute depressive symptoms resulting from bipolar disorder. The secondary objectives are to determine potential moderators and mediators of antidepressant efficacy.

Timeline

Start
2012-09
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Pioglitazone Small molecule 45 mg

Indications